(ONC) BeiGene - Ratings and Ratios

BeiGene, Ltd. (NASDAQ:ONC) is a global biotechnology company specializing in the development and commercialization of innovative cancer treatments. The company focuses on addressing unmet medical needs in oncology through a combination of internal research and strategic collaborations. Its commercial portfolio includes BRUKINSA (zanubrutinib), a BTK inhibitor approved for various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody for solid and blood cancers; and PARTRUVIX (parapib), a PARP inhibitor under evaluation for solid tumors. BeiGenes clinical pipeline spans multiple modalities, including small molecule inhibitors, monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). Key clinical assets include ociperlimab (BGB-A1217), a TIGIT inhibitor; zanidatamab, a HER2-targeted bispecific antibody; and BGB-11417, a Bcl-2 inhibitor. The company also has preclinical programs targeting emerging pathways in oncology.

BeiGene has established partnerships with leading pharmaceutical companies such as Amgen, Bristol Myers Squibb (BMS), and Novartis to expand its global reach and accelerate drug development. The company operates a robust commercial infrastructure in China and has a growing presence in the U.S. and Europe. BeiGene was founded in 2010 and is headquartered in Camana Bay, Cayman Islands. Its strategic focus on innovation, quality, and accessibility has positioned it as a key player in the global oncology landscape.